Clinical Trial Update: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update from Novartis assessing LXH254 combinations for efficacy and safety in patients with previously treated unresectable or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LXH254

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING